These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6370127)

  • 21. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of vancomycin in patients with various degrees of renal function.
    Matzke GR; McGory RW; Halstenson CE; Keane WF
    Antimicrob Agents Chemother; 1984 Apr; 25(4):433-7. PubMed ID: 6732213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
    Krakamp B; Tanswell P; Vogel H; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):75-8. PubMed ID: 2917593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefotetan elimination in patients with varying degrees of renal dysfunction.
    Wright N; Wise R; Hegarty T
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():213-6. PubMed ID: 6573319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of ceftazidime during plasmapheresis.
    Bozkurt F; Schollmeyer P; Keller E
    Eur J Clin Pharmacol; 1987; 33(2):197-201. PubMed ID: 3319644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
    Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
    Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
    Ohkawa M; Orito M; Sugata T; Shimamura M; Sawaki M; Nakashita E; Kuroda K; Sasahara K
    Antimicrob Agents Chemother; 1980 Sep; 18(3):386-9. PubMed ID: 6932824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple-dose pharmacokinetics of ceftazidime in cancer patients.
    Garcia I; Fainstein V; Smith RG; Bodey GP
    Antimicrob Agents Chemother; 1983 Aug; 24(2):141-4. PubMed ID: 6357067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
    Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
    Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.
    Ohkawa M; Takamae K; Shimamura M; Kuroda K; Awazu S
    Chemotherapy; 1981; 27(3):149-54. PubMed ID: 7226971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
    Ohkawa M; Hirano S; Tokunaga S; Motoi I; Shoda R; Ikeda A; Sugata T; Sawaki M; Shimamura M; Okasho A; Kuroda K
    Antimicrob Agents Chemother; 1983 Jan; 23(1):31-5. PubMed ID: 6572490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis.
    Ohkawa M; Nakashima T; Shoda R; Ikeda A; Orito M; Sawaki M; Sugata T; Shimamura M; Hirano S; Okumura K
    Chemotherapy; 1985; 31(6):410-6. PubMed ID: 3908006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
    Bergan T; Brodwall EK; Larsen EW
    Chemotherapy; 1983; 29(3):163-73. PubMed ID: 6872614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.